← Back
$AVTX All transactions

Avalo Therapeutics, Inc.

M 10b5-1 Plan

$ Value

$50K

Shares

3,970

Price

$13

Filed

Apr 8

Insider

Name

Doyle Mittie

Title

Chief Medical Officer

CIK

0001918845

Roles

Officer

Transaction Details

Transaction Date

2026-04-06

Code

M

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

7,592

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. | The reported securities were sold in multiple transactions at prices ranging from $18.00 to $18.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. | The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

Filing Info

Accession No.

0001918845-26-000008

Form Type

4

Issuer CIK

0001534120

Doyle Mittie's History

Date Ticker Type Value
2026-04-06 AVTX M $50K
2026-04-06 AVTX $72K
2026-04-06 AVTX M $0
2026-04-01 AVTX M $5K
2026-04-01 AVTX $11K
2026-04-01 AVTX M $0
2025-08-07 CGEM A $0

Other Insiders at AVTX (90d)

Insider Bought Sold Last
KAPLAN GILLA 2026-03-28
NEIL GARRY ARTHUR
Chief Executive Officer
2026-03-28
Lind Kevin Robert 2026-03-31
Jain Rita 2026-03-31
Chan Mitchell 2026-03-28
Sullivan Christopher Ryan
Chief Financial Officer
$271K 2026-04-02
KANTOFF AARON 2026-03-28
Doyle Mittie
Chief Medical Officer
$82K 2026-04-06
Goldman Jonathan 2026-03-28
Truex Samantha 2026-03-28